Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: Institut Pasteur International Network Annual Scientific Meeting

Open Access Lecture presentation

Vaccines for neglected diseases: challenges and opportunities

Allan Saul

  • Correspondence: Allan Saul

Author affiliations

Novartis Vaccines Institute for Global Health, 53100 Siena, Italy

Citation and License

BMC Proceedings 2011, 5(Suppl 1):L4  doi:10.1186/1753-6561-5-S1-L4

The electronic version of this article is the complete one and can be found online at: http://www.biomedcentral.com/1753-6561/5/S1/L4


Published:10 January 2011

© 2011 Saul; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lecture presentation

Infectious diseases exert a major burden of disease in developing countries with 99% of the global burden of infectious diseases, as measured by DALYs, in low and middle income countries. While better use of existing vaccines would make an appreciable difference, the greatest burden is caused by diseases for which we currently have no vaccines. The picture, especially in children, is dominated by diarrheal and respiratory diseases. Paradoxically these diseases have relatively low priority for funding in absolute terms, and especially in relationship to the burden of disease. Thus, new vaccines for these neglected diseases need both innovative scientific solutions and innovative development schemes involving scientific institutes, public financing and industrial input. The industrial input is critical: not only will vaccine manufacture require an industrial partner, but the knowledge to efficiently undertake the technical and clinical development leading to vaccine production largely resides in industry. A potentially important development in this area has been the recent formation of Industry Linked Vaccine Institutes: For example, the Novartis Vaccines Institute for Global Health and the Hilleman Laboratories. These are an important conduit for applying industrial know how for developing commercial vaccines to the pressing need for vaccines for neglected diseases of developing countries.